Health-related quality of life and its correlates in Japanese patients with myotonic dystrophy type 1

Purpose Myotonic dystrophy type 1 (DM1) is a common form of muscular dystrophy that presents with a variety of symptoms that can affect patients’ quality of life (QoL). Despite the importance of clarifying patients’ subjective experience in both physical and psychosocial aspects for improved symptom management, there is lack of evidence concerning QoL of patients with DM1 in Japan. Patients and methods A cross-sectional study was performed with 51 DM1 patients who completed questionnaires that measured health-related QoL (HRQoL), depression, and daytime sleepiness. Activities of daily living, body mass index (BMI), and genetic information were also collected, together with general demographic information. Correlation analyses using these variables were performed. Furthermore, regression analysis was utilized to assess the relationship that HRQoL, depression, and daytime sleepiness scores have with other variables. Results Physical component summary (PCS) score was affected by the disease more than the mental component summary (MCS) score among study participants. Moderate correlation was observed between PCS and depression, PCS and Barthel index, and depression and daytime sleepiness. Regression analysis revealed that age, sex, cytosine–thymine–guanine repeats, and BMI did not predict the aforementioned dependent variables. Conclusion DM1 symptoms influenced physical component scores more than mental component scores, although the state of physical wellness seemed to affect patients’ mood. Explaining the QoL of these patients only using biologic and genetic characteristics was not sufficient. We conclude that social and psychological aspects of these patients’ lives and the nature of adjustments made by patients due to DM1 to require further examination in order to improve the standard of care.

[1]  F. Mahoney,et al.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 2018, Maryland state medical journal.

[2]  T. Heskes,et al.  Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial , 2018, The Lancet Neurology.

[3]  S. Suwazono,et al.  Cognitive impairment and quality of life in patients with myotonic dystrophy type 1 , 2018, Muscle and Nerve.

[4]  E. Bonanni,et al.  Disruption of sleep-wake continuum in myotonic dystrophy type 1: Beyond conventional sleep staging , 2018, Neuromuscular Disorders.

[5]  R. Moxley,et al.  Myotonic dystrophy patient preferences in patient‐reported outcome measures , 2018, Muscle & nerve.

[6]  C. Heatwole,et al.  Prospective measurement of quality of life in myotonic dystrophy type 1 , 2017, Acta neurologica Scandinavica.

[7]  R. Kessels,et al.  The cognitive profile of myotonic dystrophy type 1: A systematic review and meta-analysis , 2017, Cortex.

[8]  V. Rakocevic-Stojanovic,et al.  Five‐year study of quality of life in myotonic dystrophy , 2016, Acta neurologica Scandinavica.

[9]  G. Bassez,et al.  Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification. , 2016, Revue neurologique.

[10]  B. Gandek,et al.  Standardizing disease-specific quality of life measures across multiple chronic conditions: development and initial evaluation of the QOL Disease Impact Scale (QDIS®) , 2016, Health and Quality of Life Outcomes.

[11]  M. Cosottini,et al.  Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study , 2016, Orphanet Journal of Rare Diseases.

[12]  Bruno Eymard,et al.  Prevalence and correlates of apathy in myotonic dystrophy type 1 , 2015, BMC Neurology.

[13]  R. Moss‐Morris Adjusting to chronic illness: time for a unified theory. , 2013, British journal of health psychology.

[14]  L. Noreau,et al.  Clinical, Psychosocial, and Central Correlates of Quality of Life in Myotonic Dystrophy Type 1 Patients , 2013, European Neurology.

[15]  D. Lavrnić,et al.  Influence of multisystemic affection on health-related quality of life in patients with myotonic dystrophy type 1 , 2013, Clinical Neurology and Neurosurgery.

[16]  Y. Dauvilliers,et al.  Daytime Sleepiness and Myotonic Dystrophy , 2013, Current Neurology and Neuroscience Reports.

[17]  R. Moxley,et al.  Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1) , 2012, Neurology.

[18]  S. Kyle,et al.  A systematic review of quality of life in adults with muscle disease , 2011, Journal of Neurology.

[19]  G. Borm,et al.  High disease impact of myotonic dystrophy type 2 on physical and mental functioning , 2011, Journal of Neurology.

[20]  L. Samuelsson,et al.  Depression in Myotonic Dystrophy type 1: clinical and neuronal correlates , 2010, Behavioral and Brain Functions.

[21]  K. Harms-Ringdahl,et al.  Perceived functioning and disability in adults with myotonic dystrophy type 1: a survey according to the International Classification Of Functioning, Disability and Health. , 2009, Journal of rehabilitation medicine.

[22]  Y. Dauvilliers,et al.  Fatigue and daytime sleepiness in patients with myotonic dystrophy type 1: To lump or split? , 2009, Neuromuscular Disorders.

[23]  S. Fukuhara,et al.  Development of a Japanese version of the Epworth Sleepiness Scale (JESS) based on item response theory. , 2009, Sleep medicine.

[24]  F. Giubilei,et al.  Health-related quality of life in myotonic dystrophy type 1 and its relationship with cognitive and emotional functioning. , 2006, Journal of rehabilitation medicine.

[25]  M. Zwarts,et al.  Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  M. Sprangers,et al.  Integrating response shift into health-related quality of life research: a theoretical model. , 1999, Social science & medicine.

[27]  S. Fukuhara,et al.  Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. , 1998, Journal of clinical epidemiology.

[28]  J E Ware,et al.  Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. , 1998, Journal of clinical epidemiology.

[29]  R Jouvent,et al.  Psychopathological and emotional deficits in myotonic dystrophy , 1998, Journal of neurology, neurosurgery, and psychiatry.

[30]  R. Korneluk,et al.  Intergenerational stability of the myotonic dystrophy protomutation. , 1993, Human molecular genetics.

[31]  J. G. Dijk,et al.  Disruption of sleep-wake rhythmicity and daytime sleepiness in myotonic dystrophy , 1993, Journal of the Neurological Sciences.

[32]  R. Korneluk,et al.  Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy , 1992, Nature Genetics.

[33]  David E. Housman,et al.  Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member , 1992, Cell.

[34]  W. Kingston Myotonic Dystrophy, 2nd Ed. , 1990, Neurology.

[35]  M. Duveneck,et al.  Depression in myotonic muscular dystrophy. , 1986, Archives of physical medicine and rehabilitation.

[36]  R. Brumback,et al.  The depression of myotonic dystrophy: response to imipramine. , 1983, Journal of neurology, neurosurgery, and psychiatry.

[37]  L. Radloff The CES-D Scale , 1977 .

[38]  H. Mayberg,et al.  Reliability, validity, and clinical correlates of apathy in Parkinson's disease. , 1992, The Journal of neuropsychiatry and clinical neurosciences.